SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.980
+0.180 (4.74%)
At close: Dec 5, 2025, 4:00 PM EST
3.900
-0.080 (-2.01%)
After-hours: Dec 5, 2025, 7:57 PM EST
SAB Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 0.11 | 1.32 | 2.24 | 23.9 | 60.88 | 55.24 | Upgrade
|
| Revenue Growth (YoY) | -92.42% | -40.94% | -90.63% | -60.73% | 10.21% | 1504.91% | Upgrade
|
| Cost of Revenue | 30.45 | 30.25 | 16.52 | 36.44 | 57.18 | 27.91 | Upgrade
|
| Gross Profit | -30.33 | -28.93 | -14.28 | -12.53 | 3.69 | 27.33 | Upgrade
|
| Selling, General & Admin | 12.03 | 13.98 | 23.8 | 16.38 | 17.09 | 6.77 | Upgrade
|
| Operating Expenses | 12.86 | 13.98 | 23.8 | 16.38 | 17.09 | 6.77 | Upgrade
|
| Operating Income | -43.19 | -42.91 | -38.08 | -28.92 | -13.39 | 20.56 | Upgrade
|
| Interest Expense | -0.25 | -0.32 | -0.32 | -0.3 | -0.29 | -0.47 | Upgrade
|
| Interest & Investment Income | 0.87 | 1.29 | 0.58 | 0.07 | 0.02 | 0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | 61.29 | 7.81 | -4.39 | 10.38 | -4.15 | 0 | Upgrade
|
| EBT Excluding Unusual Items | 18.71 | -34.13 | -42.19 | -18.76 | -17.81 | 20.12 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.03 | 0.03 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 0.02 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 0.03 | 0.67 | - | Upgrade
|
| Pretax Income | 18.74 | -34.11 | -42.19 | -18.72 | -17.14 | 20.12 | Upgrade
|
| Income Tax Expense | - | - | - | 0.03 | - | - | Upgrade
|
| Net Income | 18.74 | -34.11 | -42.19 | -18.74 | -17.14 | 20.12 | Upgrade
|
| Net Income to Common | -4.29 | -34.11 | -42.19 | -18.74 | -17.14 | 20.12 | Upgrade
|
| Shares Outstanding (Basic) | 10 | 9 | 6 | 4 | 3 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 10 | 9 | 6 | 4 | 3 | 3 | Upgrade
|
| Shares Change (YoY) | 11.66% | 67.74% | 26.86% | 59.20% | 1.21% | -23.30% | Upgrade
|
| EPS (Basic) | -0.45 | -3.68 | -7.64 | -4.31 | -6.27 | 7.92 | Upgrade
|
| EPS (Diluted) | -2.23 | -3.68 | -7.64 | -4.31 | -6.30 | 7.40 | Upgrade
|
| Free Cash Flow | -37.59 | -34.63 | -25.32 | -25.63 | -8.96 | -2.73 | Upgrade
|
| Free Cash Flow Per Share | -3.90 | -3.74 | -4.58 | -5.89 | -3.28 | -1.01 | Upgrade
|
| Gross Margin | - | - | - | -52.44% | 6.07% | 49.48% | Upgrade
|
| Operating Margin | -37657.13% | -3244.87% | -1700.56% | -120.97% | -22.00% | 37.21% | Upgrade
|
| Profit Margin | -3738.52% | -2579.03% | -1884.50% | -78.40% | -28.16% | 36.42% | Upgrade
|
| Free Cash Flow Margin | -32769.84% | -2618.65% | -1130.71% | -107.20% | -14.71% | -4.94% | Upgrade
|
| EBITDA | -40.09 | -38.12 | -34.33 | -25.63 | -11.9 | 20.94 | Upgrade
|
| EBITDA Margin | - | - | - | -107.20% | -19.55% | 37.91% | Upgrade
|
| D&A For EBITDA | 3.1 | 4.79 | 3.75 | 3.29 | 1.49 | 0.38 | Upgrade
|
| EBIT | -43.19 | -42.91 | -38.08 | -28.92 | -13.39 | 20.56 | Upgrade
|
| EBIT Margin | - | - | - | -120.97% | -22.00% | 37.21% | Upgrade
|
| Revenue as Reported | 0.11 | 1.32 | 2.24 | 23.9 | 60.88 | 55.24 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.